Tom Hanks Insulin and Type 2 Diabetes: What His Treatment Would Cost a Non-Celebrity

Tom Hanks and His Public Type 2 Diabetes Disclosure

Tom Hanks told David Letterman in October 2013 that he had been diagnosed with Type 2 Diabetes. "I went to the doctor and he said, 'You know those high blood sugar numbers you've been dealing with since you were 36? Well, you've graduated. You've got Type 2 Diabetes, young man,'" Hanks said during the interview. He was 57 at the time.

A History of Elevated Blood Sugar

Hanks described a pattern many endocrinologists recognize: years of prediabetes preceding a formal T2D diagnosis. The American Diabetes Association (ADA) estimates that 97.6 million U.S. Adults aged 18 and older have prediabetes, and roughly 80% of them do not know it 1. Hanks' trajectory from elevated fasting glucose at age 36 to a T2D diagnosis two decades later is consistent with published natural history data showing annual conversion rates of 5% to 10% from prediabetes to T2D 2.

Weight and Lifestyle Factors

Hanks has also spoken publicly about weight gain for film roles, including roughly 30 pounds gained for A Man Called Otto and significant fluctuations for Cast Away and Philadelphia. Repeated weight cycling is associated with increased insulin resistance and higher T2D risk, according to a 2017 meta-analysis published in The BMJ 3. Whether Hanks' role-related weight changes directly contributed to his diagnosis is speculative. The clinical pattern, though, tracks with known risk factors.

What Does a Standard T2D Medication Regimen Look Like?

The ADA 2024 Standards of Care recommend metformin combined with lifestyle modification as first-line therapy for most newly diagnosed T2D patients 1. From there, second-line agents are selected based on comorbidities, cardiovascular risk, cost, and patient preference.

First-Line: Metformin

Metformin is the most prescribed diabetes drug globally. It works.

Generic metformin costs between $4 and $20 per month at most retail pharmacies, and many chains like Walmart and Costco include it on their $4 generic drug lists. For a patient like Hanks, with a T2D diagnosis and no contraindications, this would be the starting point regardless of wealth.

Second-Line Options

When metformin alone does not achieve an HbA1c target of <7%, the ADA recommends adding a second agent. The choices include GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide), SGLT2 inhibitors (empagliflozin, dapagliflozin), DPP-4 inhibitors (sitagliptin, saxagliptin), sulfonylureas (glipizide, glimepiride), or insulin 1.

Each of these drug classes carries a different cost profile, and the price gap between them is where affordability becomes a real barrier for non-celebrities.

The Cost of GLP-1 Receptor Agonists for T2D

GLP-1 receptor agonists have become a preferred second-line option for T2D patients with established cardiovascular disease or high cardiovascular risk. The SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide reduced major adverse cardiovascular events by 26% compared to placebo in T2D patients with high cardiovascular risk over 2.1 years of follow-up 4.

List Prices vs. Real-World Out-of-Pocket Costs

Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg weekly injection) carries a wholesale acquisition cost (WAC) near $935 per month. Without insurance, patients pay between $900 and $1,200 at retail pharmacies. With commercial insurance, copays typically range from $25 to $150 per month depending on formulary tier. Patients on Medicare Part D face a coverage gap (the "donut hole") where out-of-pocket costs can spike before catastrophic coverage begins 5.

Trulicity (dulaglutide) runs approximately $930 per month at list price. Rybelsus (oral semaglutide) lists at roughly $935 per month as well. These are not rounding errors. They represent a major financial barrier.

What a Celebrity Can Absorb That Most Patients Cannot

Tom Hanks' estimated net worth exceeds $400 million. A $1,000 monthly medication cost represents roughly 0.003% of that figure annually. For a median-income American household earning $74,580 per year (U.S. Census Bureau, 2022), that same $1,000 monthly cost consumes 16.1% of pre-tax income. The math is not subtle.

Insulin Therapy: When T2D Progresses

Not every T2D patient requires insulin. But beta-cell function declines over time in many patients, and the UK Prospective Diabetes Study (UKPDS) demonstrated that roughly 50% of T2D patients need insulin within 6 years of diagnosis to maintain glycemic targets 6.

Basal Insulin Costs

Insulin glargine (Lantus) lists at approximately $300 to $400 per vial without insurance. Most patients use one to two vials per month depending on dose. Biosimilar insulin glargine products (Semglee, Rezvoglar) have reduced costs somewhat, with prices ranging from $150 to $250 per vial.

The Inflation Reduction Act of 2022 capped insulin copays at $35 per month for Medicare Part D beneficiaries beginning in 2023 7. Several major manufacturers (Eli Lilly, Novo Nordisk, Sanofi) subsequently announced $35 caps for commercially insured patients as well. This was a significant policy shift.

Rapid-Acting Insulin

Patients who require mealtime insulin add rapid-acting formulations like insulin lispro (Humalog) or insulin aspart (NovoLog). These carry similar per-vial costs of $275 to $350 at list price. A basal-bolus regimen combining both types could cost $600 to $1,400 per month without insurance before the copay caps.

The Uninsured Gap

The $35 cap applies only to insured patients. Approximately 27.6 million Americans lacked health insurance in 2022, according to the U.S. Census Bureau. For these individuals, insulin remains priced at full retail. The ADA has called insulin affordability a public health crisis, noting that one in four insulin-dependent patients reports rationing doses due to cost 8.

SGLT2 Inhibitors: The Cardio-Renal Benefit and Its Price Tag

SGLT2 inhibitors have demonstrated benefits beyond glucose lowering. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% in T2D patients with established cardiovascular disease 9. The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced kidney disease progression by 39% regardless of diabetes status 10.

Monthly Costs

Jardiance (empagliflozin) lists at approximately $570 to $620 per month. Farxiga (dapagliflozin) is priced similarly at $550 to $600 per month. Generic dapagliflozin became available in 2025, which may reduce costs over time, but initial generic pricing has remained high relative to older diabetes generics.

Clinical Selection

The ADA recommends SGLT2 inhibitors as preferred add-on therapy for T2D patients with heart failure or chronic kidney disease 1. A non-celebrity patient with T2D and a cardiac history would have strong clinical justification for one of these agents, but the out-of-pocket cost may push them toward a cheaper sulfonylurea (glipizide, roughly $4 to $15 per month) that lacks those cardio-renal benefits.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, stated in a 2023 ADA policy brief: "No one should have to choose between paying rent and paying for medications that can save their life. The cost barrier in diabetes care is not just an inconvenience. It is a driver of preventable complications and death" 8.

Monitoring: Blood Glucose Testing and Lab Work

Medication represents only part of the total cost of managing T2D. Monitoring adds a persistent expense that varies widely based on technology.

Fingerstick Testing

Traditional fingerstick glucose monitors cost $15 to $40 for the meter (often free with rebate). Test strips, however, cost $0.50 to $1.50 each. A patient testing four times daily spends $60 to $180 per month on strips alone. These are considered durable medical equipment and are covered by most insurance plans, but copays and formulary restrictions apply.

Continuous Glucose Monitors (CGMs)

CGMs like the Dexcom G7 or Abbott FreeStyle Libre 3 provide real-time glucose data without fingersticks. The FreeStyle Libre 3 costs approximately $75 to $150 per month with insurance. Without insurance, costs rise to $150 to $350 per month.

CGMs are increasingly recommended for T2D patients on insulin. The ADA endorses CGM use for all adults with T2D on intensive insulin regimens 1. A patient with Hanks' profile and financial resources could use any CGM without hesitation. A patient on a fixed income faces a harder calculation.

Quarterly and Annual Lab Work

Standard T2D monitoring includes HbA1c testing every 3 to 6 months ($20 to $100 per test without insurance), a comprehensive metabolic panel ($50 to $200), and annual lipid panels, kidney function tests, and eye exams. The total annual lab and specialist visit cost for an uninsured T2D patient can reach $1,500 to $3,000, according to ADA cost-of-care estimates 11.

Building a Realistic Monthly Budget: Celebrity vs. Average Patient

A complete comparison requires modeling two scenarios. The first assumes comprehensive private insurance with low copays (the kind of plan a high-net-worth individual would carry). The second assumes a typical employer-sponsored plan with moderate cost-sharing.

Scenario 1: Premium Coverage (Estimated Celebrity-Tier Plan)

| Item | Monthly Cost | |------|-------------| | Metformin 1000 mg twice daily | $4 | | Semaglutide 1 mg weekly (Ozempic) | $25 copay | | Dexcom G7 CGM | $30 copay | | Quarterly labs (amortized) | $15 | | Endocrinologist visit (amortized) | $20 | | Total | ~$94/month |

Scenario 2: Typical Employer Plan (Moderate Cost-Sharing)

| Item | Monthly Cost | |------|-------------| | Metformin 1000 mg twice daily | $10 | | Semaglutide 1 mg weekly (Ozempic, Tier 3) | $150 copay | | FreeStyle Libre 3 CGM | $75 copay | | Quarterly labs (amortized) | $40 | | Endocrinologist visit (amortized) | $60 | | Total | ~$335/month |

Scenario 3: Uninsured

| Item | Monthly Cost | |------|-------------| | Metformin 1000 mg twice daily | $15 | | Semaglutide 1 mg weekly (Ozempic) | $935 | | FreeStyle Libre 3 CGM | $250 | | Quarterly labs (amortized) | $80 | | Endocrinologist visit (amortized) | $125 | | Total | ~$1,405/month |

The annual spread between Scenario 1 and Scenario 3 is approximately $15,732. That figure exceeds 21% of median U.S. Household income.

What Hanks Has Said About Diet and Lifestyle

Hanks has not publicly disclosed specific medications. His public statements have focused on lifestyle factors. He told Radio Times in 2013 that his doctor's instructions were straightforward: "Well, the doctor said, 'If you can weigh what you weighed in high school, you'll essentially be OK.'"

The Clinical Reality of Lifestyle Alone

The Diabetes Prevention Program (DPP) trial (N=3,234) showed that intensive lifestyle modification reduced T2D incidence by 58% in prediabetic adults, compared to 31% for metformin 12. For patients who already have T2D, however, lifestyle modification alone maintains HbA1c targets in a smaller fraction of patients over time. The UKPDS data showed progressive beta-cell decline despite diet and exercise efforts 6.

Inference vs. Public Record

Hanks has not confirmed using insulin, GLP-1 agonists, or any specific diabetes medication. Any claims about his medication regimen that appear online without direct sourcing are inference. What can be stated is that a male patient diagnosed with T2D at age 57, with a body mass index that has fluctuated over decades, would very likely require pharmacotherapy beyond lifestyle modification based on ADA treatment algorithms 1.

How to Reduce T2D Medication Costs Without Celebrity Resources

Practical cost-reduction strategies exist. They require effort, but they work.

Generic Substitution

Metformin, glipizide, glimepiride, and pioglitazone are all available as low-cost generics ($4 to $20 per month). When clinically appropriate, these remain first-line options partly because of their affordability.

Manufacturer Patient Assistance Programs

Novo Nordisk offers the NovoCare Patient Assistance Program for eligible uninsured patients, providing Ozempic at no cost. Eli Lilly's Lilly Cares program covers Trulicity and Mounjaro. Eligibility typically requires income below 400% of the federal poverty level 13.

The $35 Insulin Cap

The Inflation Reduction Act's $35 monthly cap on insulin copays for Medicare beneficiaries took effect January 1, 2023. Lilly extended a $35 cap to all commercially insured and cash-paying patients for its insulin products in 2023, and Novo Nordisk and Sanofi followed with similar programs 7.

340B Program and FQHCs

Federally Qualified Health Centers (FQHCs) can access 340B drug pricing, offering medications at steep discounts. Patients who receive care at FQHCs may pay significantly less for brand-name agents than they would at retail pharmacies.

State-Level Programs

Multiple states operate their own prescription assistance programs. New York's EPIC program, for example, provides supplemental drug coverage for Medicare beneficiaries aged 65 and older with incomes up to $75,000 (single) or $100,000 (couple).

The ADA maintains a comprehensive cost-reduction resource page, and the CDC's National Diabetes Prevention Program (DPP) offers lifestyle intervention programs at low or no cost through over 2,000 participating organizations nationwide 14.